Arcus Biosciences Inc. Company Profile
NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Arcus Biosciences at a glance
Arcus Biosciences Inc. (NYSE: RCUS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Hayward, CA. Arcus Biosciences is led by Dr. Terry J. Rosen Ph.D. and employs about 601 people. The company's shares have traded publicly since 2018.
At a market capitalization of $2.27 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001724521, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Arcus Biosciences do?
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Business description based on the company's public filings.
Company information
- Legal name
- Arcus Biosciences Inc.
- Ticker
- NYSE: RCUS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Terry J. Rosen Ph.D.
- Employees
- 601
- Headquarters
- 3928 Point Eden Way, Hayward, CA, United States
- Phone
- 510 694 6200
- Website
- arcusbio.com
- IPO year
- 2018
- Market cap
- $2.27B
- SEC CIK
- 0001724521
- Latest annual report
- 10-K · Feb 25, 2026
Companies similar to Arcus Biosciences
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HCMHUTCHMED (China) Limited ADR | 13.22 | -1.71% | $2.30B | vs RCUS |
| PHVSPharvaris N.V. | 31.28 | -1.20% | $2.21B | vs RCUS |
| PRGOPerrigo Company plc | 15.94 | -0.62% | $2.21B | vs RCUS |
| NAMSNewAmsterdam Pharma Company N.V. | 18.41 | -5.64% | $2.21B | vs RCUS |
| PBHPrestige Consumer Healthcare Inc. | 49.63 | +0.06% | $2.35B | vs RCUS |
| LKFTLakefront Biotherapeutics ADR | 33.31 | -0.24% | $2.18B | vs RCUS |
| PVLAPalvella Therapeutics Inc. | 142.85 | -2.00% | $2.09B | vs RCUS |
| MBXMBX Biosciences Inc. | 49.55 | -7.23% | $2.46B | vs RCUS |